On July 15, Elevance reported second-quarter results that included $49.8 billion in net revenue (above FactSet consensus of $48.8 billion) and adjusted EPS of $7.45 (above consensus of $6.21). Management only increased its 2026 EPS guidance by $0.25, though.
Elevance continues to use its scale-related advantages for the benefit of clients, and we remain intrigued by its ongoing efforts to align incentives with caregivers, including the deployment of high performance provider networks.
Bears
The insurance and PBM industries will likely remain targets of regulators aiming to reduce the healthcare cost burden on society, which is its key ESG risk, in our opinion.
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 46 million medical members as of June 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.